



PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0037

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Application Number	10/655,827
Filing Date	September 5, 2003
First Named Inventor	Martin Geppert
Art Unit	1632
Examiner Name	not yet assigned
Attorney Docket Number	01269.US1

Total Number of Pages in This Submission

**ENCLOSURES (Check all that apply)**

- |  |   |   |
|--|---|---|
| <input checked="" type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Fee Attached<br><input type="checkbox"/> Amendment/Reply<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Extension of Time Request<br><input type="checkbox"/> Express Abandonment Request<br><input checked="" type="checkbox"/> Information Disclosure Statement<br><input type="checkbox"/> Certified Copy of Priority Document(s)<br><input type="checkbox"/> Response to Missing Parts/ Incomplete Application<br><input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)<br><input type="checkbox"/> Licensing-related Papers<br><input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation<br>Change of Correspondence Address<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Request for Refund<br><input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance communication to Group<br><input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences<br><input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)<br><input type="checkbox"/> Proprietary Information<br><input type="checkbox"/> Status Letter<br><input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):<br>A return-receipt postcard is enclosed. |
|--|---|---|

Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual name	Pharmacia & Upjohn Company	Edward F. Rehberg 34,703
Signature		
Date	5-07-04	

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.


Typed or printed name	JULIE K. LYONS
-----------------------	----------------

Signature	
-----------	--

Date	May 7, 2004
------	-------------

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/17 (10-03)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

(\$)**180.00****Complete if Known**Application Number **10/655,827**Filing Date **September 5, 2003**First Named Inventor **Martin Geppert**Examiner Name **not yet assigned**Art Unit **1632**Attorney Docket No. **01269.US1****METHOD OF PAYMENT (check all that apply)**☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:Deposit  
Account  
Number  
Deposit  
Account  
Name**21-0718****Pharmacia & Upjohn Company**

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments☐ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	
SUBTOTAL (1)					(\$) <b>0.00</b>

**2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE**

Total Claims		Extra Claims		Fee from below		Fee Paid
Independent	Multiple Dependent	-20** =	-3** =	0	0	
				\$0.00	\$0.00	\$0.00
				\$0.00	\$0.00	\$0.00
				\$0.00	\$0.00	\$0.00

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)**0.00**

\*\*or number previously paid, if greater; For Reissues, see above

**FEE CALCULATION (continued)****3. ADDITIONAL FEES**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	<b>180.00</b>
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) \_\_\_\_\_

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)**180.00****SUBMITTED BY**

(Complete if applicable)

Name (Print/Type)	<b>Edward F. Rehberg</b>	Registration No.	<b>34,703</b>	Telephone	<b>(269) 833-7829</b>
Signature	<i>Edward F. Rehberg</i>	(Attorney/Agent)		Date	<b>5-07-04</b>

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.


05/11/2004 SZEDIE1 00000086 210718 10655827

01 FC:1606 180.00 DA


<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>				Atty. Docket No. <b>01269</b>		Serial No. <b>10/655,827</b>	
				Applicant <b>Martin Geppert</b>			
				Filing Date <b>Sept. 5, 2003</b>		Group	


OFFICE  
 MAY 10 2004  
 PATENT & TRADEMARK

U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate	
	AA							
	AB							
	AC							
	AD							
	AE							
	AF							
	AG							
	AH							
	AI							
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	AJ							
	AK							
	AL							
	AM							
	AN							
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)								
	AO	Ambros, Victor, <i>"microRNAs: Tiny Regulators with Great Potential"</i> , Cell, Vol. 107, Pages 823-826, (Dec. 28, 2001).						
	AP	Babinet, Charles & Michel Cohen-Tannoudji, <i>"Genome engineering via homologous recombination in mouse embryonic stem (ES) cells: an amazingly versatile tool for the study of mammalian biology"</i> , An. Acad. Bras. Cienc., Vol. 73(3), Pages 365-383, (2001).						
	AQ	Bargmann, Cornelia I., <i>"High-throughput reverse genetics: RNAi screens in <i>Caenorhabditis elegans</i>"</i> , Genome Biology, Vol. 2(2), Pages 1005.1-1005.3, (2001).						
	AR	Bass, Brenda L., <i>"Double-Stranded RNA as a Template for Gene Silencing"</i> , Cell, Vol. 101(3), Pages 235-238 (April 28, 2000).						
	AS	Baulcombe, David C., <i>"Unwinding RNA Silencing"</i> , Science, Vol. 290, Pages 1108-1109, (Nov. 10, 2000).						
	AT	Bernstein, Emily, et al., <i>"Role for a bidentate ribonuclease in the initiation step of RNA interference"</i> , Nature,						

 <p>REFERENCES CITED BY APPLICANT (Use several sheets if necessary)</p>		Atty. Docket No. 01269	Serial No. 10/655,827
		Applicant Martin Geppert	
		Filing Date Sept. 5, 2003	Group
		Vol. 409, Pages 363-366, (Jan. 18, 2001).	
	AV	Brummelkamp, Thijn R., et al., "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells", Science, Vol. 296, Pages 550-553, (April 19, 2002).	
	AW	Cogoni, Carlo and Giuseppe Macino, "Post-transcriptional gene silencing across kingdoms", Current Opinion in Genetic Development, Vol. 10, Pages 638-643, (2000).	
	AX	de Angelis, Martin Hrabé, et al., "Genome-wide, large-scale production of mutant mice by ENU mutagenesis", Nature Genetics, Vol. 25, Pages 444-447, (Aug. 2000).	
	AY	de Angelis, Martin Hrabé and Mark Strivens, "Large-scale production of mouse phenotypes: The search for animal models for inherited diseases in humans", Briefings in Bioinformatics, Vol. 2(2), Pages 170-180, (May 2001).	
	AZ	Eggan, Kevin, et al., "Male and female mice derived from the same embryonic stem cell clone by tetraploid embryo complementation", Nature Biotechnology, Vol. 20, Pages 455-459, (May 2002).	
	BA	Eggan, Kevin, et al., "Hybrid vigor, fetal overgrowth, and viability of mice derived by nuclear cloning and tetraploid embryo complementation", PNAS, Vol. 98(11), Pages 6209-6214, (May 22, 2001).	
	BB	Elbashir, Sayda M., et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", Nature, Vol. 411, Pages 494-498, (May 24, 2001).	
	BC	Fire, Andrew, "RNA-triggered gene silencing", Trends in Genetics, Vol. 15(9), Pages 358-363, (Sept. 1999).	
	BD	Fire, Andrew, et al., "Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> ", Nature, Vol. 391, Pages 806-811 (Feb. 19, 1998).	
	BE	Fraser, Andrew G., et al., "Functional genomic analysis of <i>C. elegans</i> chromosome I by systematic RNA interference", Nature, Vol. 408, Pages 325-330 (Nov. 16, 2000).	
	BF	Fussenegger, Martin, "The Impact of Mammalian Gene Regulation Concepts on Functional Genomic Research, Metabolic Engineering, and Advanced Gene Therapies", Biotechnology Progress, Vol. 17, Pages 1-51, (2001).	
	BG	Hannon, Gregory J., "RNA interference", Nature, Vol. 418, Pages 244-251, (July 11, 2002).	
	BH	Kasschau, Kristin D. and James C. Carrington, "A Counterdefensive Strategy of Plant Viruses: Suppression of Posttranscriptional Gene Silencing", Cell, Vol. 95, Pages 461-470, (Nov. 13, 1998).	
	BI	Kawasaki, Hiroaki, et al., "Identification of genes that function in the TNF- $\alpha$ -mediated apoptotic pathway using randomized hybrid ribozyme libraries", Nature Biotechnology, Vol. 20, Pages 376-380, (April 2002).	
	BJ	Ketting, René F., et al., "mut-7 of <i>C. elegans</i> , Required for Transposon Silencing and RNA Interference, Is a Homolog of Werner Syndrome Helicase and RNaseD", Cell, Vol. 99, Pages 133-141, (Oct. 15, 1999).	
	BK	Knight, Scott W. and Brenda L. Bass, "A Role for the RNase III Enzyme DCR-1 in RNA Interference and Germ Line Development in <i>Caenorhabditis elegans</i> ", Science, Vol. 293, Pages 2269-2271, (Sept. 21, 2001).	
	BL	Kolb, Andreas F., "Genome Engineering Using Site-Specific Recombinases", Cloning and Stem Cells, Vol. 4(1), Pages 65-80, (2002).	
	BM	Lagos-Quintana, Mariana, et al., "Identification of Novel Genes Coding for Small Expressed RNAs", Science, Vol. 294, Pages 853-858, (Oct. 26, 2001).	
	BN	Lau, Nelson C., et al., "An Abundant Class of Tiny RNAs with Probable Regulatory Roles in <i>Caenorhabditis elegans</i> ", Science, Vol. 294, Pages 858-862, (Oct. 26, 2001).	



<p>LIST OF REFERENCES CITED BY APPLICANT</p> <p>(Use separate sheets if necessary)</p> 		Atty. Docket No.	Serial No.
		01269	10/655,827
		Applicant	Martin Geppert
		Filing Date	Sept. 5, 2003
		Group	
	BO	Lee, Naoki, et al., "Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells", Nature Biotechnology, Vol. 19, Pages 500-505, (May 2002).	
	BP	Lee, Rosalind C. and Victor Ambros, "An Extensive Class of Small RNAs in <i>Caenorhabditis elegans</i> ", Science, Vol. 294, Pages 862-864, (Oct. 26, 2001).	
	BQ	Li, Wan Xiang and Shou Wei Ding, "Viral suppressors of RNA silencing", Current Opinion in Biotechnology, Vol. 12, Pages 150-154, (2001).	
	BR	Lin, Rueyling and Leon Avery, "Policing rogue genes", Nature, Vol. 402, Pages 128-129, (Nov. 11, 1999).	
	BS	Lipardi, Concetta, Qin Wei and Bruce M. Paterson, "RNAi as Random Degradative PCR: siRNA Primers Convert mRNA into dsRNAs that are Degraded to Generate New siRNAs", Cell, Vol. 107, Pages 297-307, (Nov. 2, 2001).	
	BT	Llave, Cesar, Kristin D. Kasschau and James C. Carrington, "Virus-encoded suppressor of posttranscriptional gene silencing targets a maintenance step in the silencing pathway", PNAS, Vol. 97(24), Pages 13401-13406, (Nov. 21, 2000).	
	BU	Maeda, Ikuma, et al., "Large-scale analysis of gene function in <i>Caenorhabditis elegans</i> by high-throughput RNAi", Current Biology, Vol. 11(3), Pages 171-176, (2001).	
	BV	Misra, Ravi P., et al., "Generation of single-copy transgenic mouse embryos directly from ES cells by tetraploid embryo complementation", BMC Biotechnology, Vol. 1(12), Page 1-9, (Dec. 18, 2001).	
	BW	Miyagishi, Makoto and Kazunari Taira, "U6 promoter-driven siRNAs with four uridine 3'-overhangs efficiently suppress targeted gene expression in mammalian cells", Nature Biotechnology, Vol. 19, Pages 497-500, (May 2002).	
	BX	Paddison, Patrick J., et al., "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells", Genes & Development, Vol. 16, Pages 948-958, (2002).	
	BY	Paul, Cynthia P., et al., "Effective expression of small interfering RNA in human cells", Nature Biotechnology, Vol. 29, Pages 505-508, (May 2002).	
	BZ	Romano, Nicoletta and Giuseppe Macino, "Quelling: transient inactivation of gene expression in <i>Neurospora crassa</i> by transformation with homologous sequences", Molecular Microbiology, Vol. 6(22), Pages 3343-3353, (1992).	
	CA	Ruvkun, Gary, "Glimpses of a Tiny RNA World", Science, Vol. 294, Pages 797-799, (Oct. 26, 2001).	
	CB	Sharp, Phillip A., "RNA interference - 2001", Genes & Development, Vol. 15, Pages 485-490, (2001).	
	CC	Sijen, Titia, et al., "On the Role of RNA Amplification in dsRNA-Triggered Gene Silencing", Cell, Vol. 107, Pages 465-476, (Nov. 16, 2001).	
	CD	Sui, Guangchao, et al., "A DNA vector-based RNAi technology to suppress gene expression in mammalian cells", PNAS, Vol. 99(8), Pages 5515-5520, (April 16, 2002).	
	CE	Tabara, Hiroaki, et al., "The rde-1 Gene, RNA Interference, and Transposon Silencing in <i>C. elegans</i> ", Cell, Vol. 99, Pages 123-132, (Oct. 15, 1999).	
	CF	Wianny, Florence and Magdalena Zernicka-Goetz, "Specific interference with gene function by double-stranded RNA in early mouse development", Nature Cell Biology, Vol. 2, Pages 70-75, (Feb. 2000).	
	CG	Zamore, Phillip D., "RNA interference: listening to the sound of silence", Nature Structural Biology, Vol. 8(9),	

<p>LIST OF REFERENCES CITED BY APPLICANT</p> <p><i>(Use several sheets if necessary)</i></p> 	<p>Atty. Docket No.</p> <p>01269</p>	<p>Serial No.</p> <p>10/655,827</p>
	<p>Applicant      Martin Geppert</p>	
	<p>Filing Date      Sept. 5, 2003</p>	<p>Group</p>
<p>Pages 746-750, (Sept. 2001).</p>		
<p>Examiner</p>	<p>Date Considered</p>	